What Eve Technologies does

Eve Technologies Corporation is a Calgary, Alberta-based specialty bioanalytical services provider founded in 2004 as the first Canadian company to adopt multiplex bead assay technology for biomedical research. The company runs two core immunoassay platforms — Luminex/Bio-Plex (using color-coded polystyrene beads analyzed on a Bio-Plex 200 dual-laser system) and Meso Scale Discovery's electrochemiluminescence S-PLEX platform — to deliver quantitative, multiplexed biomarker data from small (2–25 µL) sample volumes across nine species (human, mouse, rat, porcine, canine, equine, sheep, bovine, chicken).

Service revenue is generated almost entirely on a pay-per-sample basis through three commercial lines: (1) Discovery Assays, pre-configured multiplex panels publicly priced starting at $1.45 per cytokine target per sample, marketed as the world's most affordable cytokine arrays; (2) Custom Plex Assays, project-quoted custom panels drawn from a menu of 900+ analytes across cytokines, chemokines, cardiovascular, cancer, neuroscience, and bone metabolism categories; and (3) MSD Discovery Assays, an ultra-high-sensitivity add-on for femtogram/mL detection of low-abundance biomarkers. A separately operated CLIA-certified subsidiary, Eve Diagnostics, extends the offering into regulated clinical diagnostic testing in General Immunology.

The customer base spans academic and biomedical researchers, pharmaceutical and biotech companies, government and public health agencies, and clinical diagnostic laboratories (notably through the Mitogen Advanced Diagnostics partnership for autoimmunity). Distribution is direct: customers order online or via phone-based scientific consultation (Ext. 100 for orders, Ext. 200 for lab/results), then ship samples to the Calgary facility. The company claims 4,000+ cited publications, 1.8M+ samples tested, 40M+ data points generated, and 25,000+ clients served globally across all continents. Core technology dependencies include reagent supply and instrument service contracts with Bio-Rad, EMD Millipore, and MSD, and a research collaboration with the University of Calgary's Institute of Infection, Immunity & Inflammation.

Name

Eve Technologies

Legal name

Eve Technologies Corporation

Website

https://evetechnologies.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Eve Technologies Corporation, founded in 2004 in Calgary, provides pay-per-sample multiplex biomarker assay services using Luminex and MSD platforms to academic researchers, pharmaceutical companies, and clinical diagnostic laboratories worldwide.

Ownership category

akta.pro rank

Product category

Biomedical Assay Services

NAICS

Scientific Research and Development Services (5417), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industry

Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• Multiplex assay services
• Biomarker analysis
• Cytokine profiling
• Immunoassay testing
• Clinical diagnostics

Headquarters

HQ city

Calgary

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Assay Services - Pay Per Sample: Eve Technologies generates revenue primarily through assay testing services billed on a per-sample basis. Customers select from Discovery Assays (pre-configured panels at fixed per-sample pricing) or Custom Plex Assays (custom-configured panels quoted per project). There are no restrictions on sample quantity for routine assays. Additional fees apply for non-conforming sample tubes ($3/surcharge per sample).

Pricing tiers

Distribution channels2 records

Marketing channels4 records

Core offering

Eve Technologies provides multiplex immunoassay testing services for biomedical and life science researchers using Luminex/Bio-Plex and Meso Scale Discovery platforms. Customers select from pre-configured Discovery Assays (starting at $1.45 per cytokine target) or build Custom Plex Assays from a 900+ analyte menu spanning nine species, ship samples to the Calgary lab, and receive quantitative biomarker results. The Eve Diagnostics CLIA-certified division extends the service into clinical diagnostic testing.

Product overview

Eve Technologies offers a portfolio of multiplex assay services primarily centered on two core offerings: Discovery Assays (pre-configured, most affordable cytokine panels starting at $1.45 per target across 9 species) and Custom Plex Assays (flexible custom panels from 900+ analyte menu). The company also provides MSD Discovery Assays as an add-on module for ultra-sensitive detection needs. Clinical services are delivered through the CLIA-certified Eve Diagnostics sub-brand. All services follow a pay-per-sample model where researchers select assays, submit samples, and receive quantified biomarker results.

Differentiator

Problem solved

Functional benefit

Brands

• Discovery Assays: Pre-configured multiplex assay service offering competitive pricing starting at $1.45 per cytokine target, with inclusive assay services and result reporting.
• Custom Plex Assays
• Eve Diagnostics

Products and services

• Discovery Assays Pre-configured multiplex assay panels for cytokine, chemokine, and growth factor quantification across nine species, priced pay-per-sample starting at $1.45 per analyte target with no minimum sample quantity. Designed for biomedical and life science researchers needing reproducible, quantitative immunoassay data without running assays in-house.
• Custom Plex Assays Customizable multiplex assay service allowing researchers to select specific analytes from a repertoire of 900+ targets across multiple species, with project-based quoting and 5-15 business day turnaround. Targets can be combined from research areas including cytokines, cancer biomarkers, cardiovascular markers, neuroscience markers, and bone metabolism markers.
• MSD Discovery Assays Assay services utilizing the Meso Scale Discovery (MSD) electrochemiluminescence platform, offering ultra-high sensitivity (femtogram/mL) detection of low-abundance biomarkers in single and multi-plex formats. Designed for neurology, cytokine, and other biomarker applications requiring sensitivity 100-1000x beyond standard ELISA.
• Eve Diagnostics CLIA-certified clinical laboratory division of Eve Technologies providing high-complexity diagnostic testing in General Immunology, including Laboratory Developed Tests (LDTs) for clinical cytokine testing. Serves physicians, referring labs, and clinical diagnostics partners.

Quantifiable outcome

• Prices starting at $1.45 per cytokine target per sample — more cost-effective than in-house assays
• +4 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and major.

• Meso Scale Discovery (MSD)coreTechnology or IntegrationMSD is a global leader in innovative assay technology with proprietary MULTI ARRAY platform enabling simultaneous measurement of multiple biomarkers. Eve Technologies has partnered with MSD to expand assay services, offering clients enhanced accuracy and sensitivity through MSD's electrochemiluminescence platform. Eve Technologies offers both pre-configured MSD Discovery Assays and custom MSD-based panels.
• EMD Millipore (Milliplex)coreTechnology or IntegrationEMD Millipore produces the most extensive multiplex analyte lists and panels in the industry under the MILLIPLEX trade name. Eve Technologies regularly assesses their multiplex kits and utilizes these kits in client research projects. Milliplex kits form a core component of Eve Technologies' assay menu.
• Bio-Rad (Bio-Plex)coreTechnology or IntegrationBio-Rad has fully adopted Multiplexing LASER Bead Technology under their Bio-Plex trade name, marketing both multiplex kits and bead analyzer machines (Bio-Plex 200). Eve Technologies assesses and utilizes Bio-Rad's kits, and has awarded Bio-Rad a service contract to maintain the Bio-Plex 200 machine used in their lab.
• The Institute of Infection, Immunity & InflammationmajorStrategic or Co-development PartnerOne of the largest biomedical institutes in Alberta, home to world-class researchers and clinicians focused on infection, immunity, and inflammation. Many institute members partner with Eve Technologies to accelerate their research initiatives, providing Eve Technologies with high-profile academic collaborations.
• Mitogen Advanced DiagnosticsmajorStrategic or Co-development PartnerMitogen Advanced Diagnostics is a diagnostic laboratory specializing in autoimmune diagnostics with tests including ANA, ENA, and CCP. As a long-time client, Mitogen and Eve Technologies work together to facilitate large studies in autoimmunity, combining diagnostic expertise with Eve Technologies' multiplex assay capabilities.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Bio-Rad Laboratories: Markets the Bio-Plex 200 multiplex suspension array system and reagent kits that Eve Tech uses and resells — a broader life-science tools incumbent with overlapping capabilities but a fundamentally different business model (instruments and consumables).
• Charles River Laboratories: Large preclinical CRO offering discovery, pharmacology, and biomarker services to pharma and biotech — a scaled incumbent whose preclinical service portfolio overlaps with Eve Tech's drug-discovery and preclinical customer work.
• Meso Scale Diagnostics (MSD): Develops and sells the MULTI-ARRAY electrochemiluminescence platform and S-PLEX assays that Eve Tech runs as its high-sensitivity offering — a core technology partner that also provides its own services and is therefore both a vendor and adjacent competitor.
• MilliporeSigma (EMD Millipore): Produces the Milliplex multiplex analyte kits that Eve Tech purchases and runs as a core component of its menu — a much larger life-science tools incumbent supplying Eve Tech while also selling into the same end customers.
• Laboratory Corporation of America (LabCorp / Covance): Operates a global clinical diagnostics and CRO network (including Covance) that competes with Eve Tech's Eve Diagnostics division for clinical testing volume and with its pharma services for biomarker and trial-support work.
• Eurofins Scientific: Global CRO with extensive biomarker, immunoassay, and clinical-trial laboratory services across pharma and academic customers — broad incumbent competing for the same pharma/biotech wallet share that Eve Technologies addresses.

Emerging players

• Olink: Offers next-generation proximity-extension assay (PEA) protein biomarker services and kits, increasingly competing with Luminex-based multiplexing for biomarker discovery and pharma research applications.
• SomaLogic: Operates the SomaScan proteomics platform providing high-multiplex protein measurement services to researchers and pharma — represents a competing next-generation alternative to multiplex immunoassays like those offered by Eve Technologies.

Direct peers

• Quanterix: Provides ultra-sensitive protein detection services (Simoa platform) for biomarker research and clinical diagnostics — directly competes with Eve Tech's MSD S-PLEX offering in the high-sensitivity biomarker niche.
• Myriad Genetics (Myriad RBM): Operates the Myriad RBM multiplex biomarker services division, which offers quantitative immunoassay panels using Luminex-based technology to pharma and academic researchers — directly comparable service model and customer base to Eve Technologies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eve-technologies

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eve Technologies